Introduction {#s1}
============

Metastatic gastric tumor originating from breast cancer (MGTBC) is a rare clinical entity \[[@R01]\] and its clinicopathological features have not yet been clarified. Several studies have reported that the most common histological type of MGTBC is invasive lobular carcinoma (ILC), although it is less common than infiltrating ductal carcinoma (IDC) in primary breast cancer \[[@R01], [@R02]\]. The endoscopic appearance of MGTBC is classified into two types, gastric cancer (GC)-like lesions and submucosal tumors (SMT) \[[@R03]\]. There have been no reports of relationships between endoscopic characteristics and clinical features in either of the types so far. Diagnostically, it is sometimes difficult to determine whether a GC-like lesion is a gastric metastatic tumor or a primary gastric tumor, especially a Borrmann type 4 lesion. The treatment strategy is different for primary GC and MGTBC, so it is important to diagnose them precisely. Generally, MGTBC is treated with systemic therapy based on Stage IV breast cancer treatment \[[@R04]\]; however, there is no evidence-based therapy available for this treatment method. In this study, we observed the endoscopic appearances and clinical courses in 11 patients with MGTBC and analyzed their clinicopathological features.

Materials and Methods {#s2}
=====================

From 2006 to 2016, we performed 57,952 cases of esophagogastroduodenoscopy (EGD), and there were 11 patients (0.019%) with MGTBC who were treated at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. All the gastric lesions were diagnosed as MGTBC by histology. We investigated their clinicopathological characteristics by medical chart review (age, sex, complaint, TNM stage of primary breast cancer, histological type, endoscopic findings, metastatic site, hormonal receptor status of specimen, and survival outcome). The presence of oligometastatic breast cancer was determined based on clinical evaluation and systemic radiographic imaging demonstrating fewer than five metastatic lesions. All patients provided comprehensive written informed consent. The institutional review board of the Cancer Institute Hospital of the Japanese Foundation for Cancer Research approved this study and it was conducted in accordance with the Declaration of Helsinki 1964 and its later amendments.

Statistical analysis was carried out using EZR (Saitama Medical Center, Jichi Medical University, Saitama Japan) which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander designed to add statistical functions frequently used in biostatistics. We compared the categorical parameters using the Fisher's exact test and continuous parameters using the Mann-Whitney U-test. Overall survival (OS) was calculated from the date of diagnosis of gastric metastasis until death from any cause or the last follow-up date. The time to survival curve was established using the Kaplan-Meier method. In all analyses, P-value less than 0.05 was determined to be statistically significant.

Results {#s3}
=======

Characteristics of primary breast cancer {#s3a}
----------------------------------------

All 11 patients were women, with a median age of 57 years (range, 33 - 76 years, [Table 1](#T1){ref-type="table"}). Histological examination revealed six cases (54.5%) with solid tubular components and five cases (45.5%) with ILC components. Five patients (45.5%) had Stage IV disease according to the Union for International Cancer Control, 7th edition (UICC7th) and four patients (36.4%) underwent curative resection. There were no significant differences between patients underwent curative mastectomy and patients with residual cancer after mastectomy in median survival time from diagnosis of primary breast cancer (median survival time; 163 vs. 89.8 months, Hazard ratio; 2.14, P = 0.399) and from gastric metastasis (median survival time; 16.0 vs. 37.2 months, Hazard ratio; 0.187, P = 0.146).

###### Characteristics of Primary Breast Cancer Patients

  Case   Age (years)/sex   Location of cancer   TNM stage   Metastatic organs                Histological type   Residual cancer after surgery
  ------ ----------------- -------------------- ----------- -------------------------------- ------------------- -------------------------------
  1      33/F              Left                 IIA         \-                               Solid-tubular       R0
  2      58/F              Left                 IV          Liver, adrenal gland, pancreas   Solid-tubular       R2
  3      72/F              Right                IIA         \-                               Scirrous            R0
  4      57/F              Left                 IIIC        \-                               Lobular             R1
  5      53/F              Left                 IV          Bone                             Scirrous            R2
  6      49/F              Left                 IV          Skin                             Scirrous/lobular    No surgery
  7      64/F              Left                 IIIC        \-                               Scirrous/lobular    R1
  8      76/F              Left                 IIB                                          Scirrous            R0
  9      63/F              Left                 IV          Adrenal gland, skin, brain       Scirrous            R2
  10     47/F              Right                IV          Bone, liver                      Lobular             R2
  11     57/F              Left                 I                                            Lobular             R0

F: female.

Clinical characteristics and prognosis of MGTBC {#s3b}
-----------------------------------------------

Among the clinical symptoms of MGTBC, melena was the most common (27.3%); however, asymptomatic cases were also common ([Table 2](#T2){ref-type="table"}). Three patients (27.3%) had upper abdominal symptoms of epigastric pain and heartburn. Gastric specimens from nine patients were subjected to a hormonal receptor test, and all were positive for the estrogen receptor (ER). Seven patients of human epidermal growth factor receptor 2 (HER2) with immunohistochemistry test were all negative. Seven and four cases had GC-like lesions and SMTs, respectively ([Fig. 1](#F1){ref-type="fig"}). Of the 11 cases, six had Borrmann type 4-like lesions. The median period from primary breast cancer diagnosis to the detection of gastric metastases was 60 months (range, 19 - 178 months). The median OS in all patients was 26 months (range, 1 - 42 months; [Fig. 2](#F2){ref-type="fig"}), and that in the patients treated with chemotherapy after the diagnosis of gastric metastases was significantly better than that in those who did not receive chemotherapy with supportive care (median OS; 28.9 vs. 3.80 months, Hazard ratio; 8.27, P = 0.047). Oligometastatic breast cancer (metastatic lesions; n ≤ 5) also has significantly better outcome than those which had more than six metastatic lesions (median OS; 39.4 vs. 26.4 months, Hazard ratio; 3.17, P = 0.0239).

###### Characteristics of Patients With Gastric Metastasis From Breast Cancer

  Case   Complaint         Macroscopic findings   Metastatic site   Hormonal receptor of biopsy specimen   HER2 status\*\*\*\*   Chemotherapy   Metastatic lesion^a^   Elapse time^b^ (months)   Survival time^c^ (months)   Outcome
  ------ ----------------- ---------------------- ----------------- -------------------------------------- --------------------- -------------- ---------------------- ------------------------- --------------------------- ---------
  1      Melena            SMT\*                  M                 \-                                     \-                    \-             Innumerable            19                        1                           Died
  2      Melena            SMT                    U                 \-                                     \-                    \+             5                      40                        28                          Alive
  3      Heartburn         SMT                    ML                ER^\*\*^+, PgR^\*\*\*^+                1+                    \+             11                     100                       28                          Alive
  4      Asymptomatic      SMT                    L                 ER+, PgR-                              1+                    \-             1                      105                       19                          Alive
  5      Melena            Borrmann type 3        M                 ER+, PgR-                              0                     \+             5                      69                        42                          Died
  6      Asymptomatic      Borrmann type 4        UML               ER+, PgR+                              1+                    \+             Innumerable            39                        1                           Alive
  7      Epigastric pain   Borrmann type 4        UM                ER+, PgR-                              1+                    \+             1                      46                        37                          Died
  8      Anorexia          Borrmann type 4        M                 ER+, PgR-                              1+                    \+             Innumerable            112                       6                           Died
  9      Vomiting          Borrmann type 4        L                 ER+, PgR+                              \-                    \-             Innumerable            58                        4                           Died
  10     Asymptomatic      Borrmann type 4        M                 ER+                                    \-                    \+             12                     61                        29                          Died
  11     Epigastric pain   Borrmann type 4        ML                ER+, PgR-                              1+                    \+             2                      181                       26                          Died

^\*^Submucosal tumor. ^\*\*^Estrogen receptor. \*\*\*Progesterone receptor. \*\*\*\*Human epidermal growth factor receptor 2 with Immunohistochemistry test. ^a^Number of metastatic lesion in whole body. ^b^From diagnosis of breast cancer to gastric metastasis. ^c^From diagnosis of gastric metastasis.

![White light endoscopic features of 11 patients with gastric metastasis of breast cancer.](wjon-09-04-104-g001){#F1}
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GC-like lesion vs. SMT {#s3c}
----------------------

We compared GC-like lesions with SMTs. We analyzed the effect of age, presence or absence of symptoms, histology, number of lesions, and whether or not chemotherapy was performed after a diagnosis of MGTBC; there were no significant differences in OS with any of the factors. Six of the seven cases had GC-like lesions with peritoneal metastasis, whereas none of the SMT cases had peritoneal metastasis (P = 0.015, [Table 3](#T3){ref-type="table"}).

###### Comparison of Characteristics Between Gastric Cancer (GC)-Like Lesion and SMT

                                                                                              GC -like lesion (N = 7)   SMT (N = 4)     P value
  ------------------------------------------------------------------------------------------- ------------------------- --------------- ---------
  Age, years, median (range)                                                                  57 (49 - 76)              57 (33 - 72)    0.925
  Symptomatic (%)                                                                             5 (71)                    3 (75)          1
  Peritoneal metastasis (%)                                                                   6 (86)                    0 (0)           0.0152
  Invasive lobular carcinoma (%)                                                              4 (57)                    1 (25)          0.545
  Multiple lesions (%)                                                                        6 (86)                    2 (50)          0.491
  Chemotherapy after diagnosis of gastric metastasis (%)                                      6 (86)                    2 (50)          0.491
  Survival time from diagnosis of breast cancer, months, median (range)                       90 (40 - 207)             96 (20 - 127)   1
  Elapse time from diagnosis of breast cancer to gastric metastases, months, median (range)   61(39 - 181)              70(19 - 106)    0.571
  Survival time from gastric metastasis, months, median (range)                               26(4 - 37)                23(1 - 28)      0.571

A case with transformation of the endoscopic appearance from SMT to a GC-like lesion {#s3d}
------------------------------------------------------------------------------------

On temporal observation, there was a patient whose lesion showed gradual transformation from an SMT-type lesion to a lesion with a Borrmann type 4-like appearance.

In case No. 4, a 57-year-old woman was found to have a gastric tumor using EGD during a regular health check-up. Her height was 155 cm, weight was 56 kg, and body surface area was 1.54 m^2^. Her medical history included breast cancer surgery (pT3pT3M0, pStage IIIC according to UICC 7th) 105 months ago and adjuvant chemotherapy with CAF (cyclophosphamide (500 mg/m^2^ intravenously (IV), day 1), doxorubicin (50 mg/m^2^ IV, day 1), and 5-fluorouracil (500 mg/m^2^ IV, day 1)) in six courses without severe adverse effects. In our examination, EGD demonstrated an SMT lesion in the greater curvature of the gastric antrum ([Fig. 3A, B](#F3){ref-type="fig"}). One year later, EGD showed enlargement of this lesion and thickening of the wall in lesser curvature of gastric angle ([Fig. 3C, D](#F3){ref-type="fig"}). One and a half years later, EGD revealed stenosis of the lumen in the gastric antrum and diffuse thickening of the gastric wall that resembled Borrmann type 4 disease ([Fig. 3E, F](#F3){ref-type="fig"}). Simultaneously, computed tomography (CT) showed the presence of a peritoneal metastasis. The patient has survived and is currently receiving palliative care.

![The case of macroscopic type progressed from submucosal tumor to Borrmann type 4.](wjon-09-04-104-g003){#F3}

Discussion {#s4}
==========

The incidence of MGTBC is estimated to be approximately 11.6% based on the results of autopsy series on patients with breast cancer. Nevertheless, gastric metastases are uncommon entities in clinical practice and were only identified in 3.5% of the aforementioned patients while they were alive \[[@R03]\]. Histologically, MGTBC are common in ILC. Metastasis to the lung, liver, bone, and brain from breast cancer are more common for IDC than for ILC. In addition, it is more common for ILC than IDC to metastasize to the gastrointestinal tract, peritoneum, and ovary \[[@R05]\]. In Japan, MGTBC is especially rare, as the incidence of ILC (3.7%) is lower than that in the United States (8-14%) \[[@R01], [@R02], [@R06]\].

As shown in [Table 2](#T2){ref-type="table"}, some patients with gastric metastases were asymptomatic, whereas others had nonspecific symptoms; therefore, it was difficult to diagnose gastric metastases only on the basis of clinical symptoms. The median OS of patients with MGTBC was 11 months in a previous study \[[@R07]\], and the clinical result in our hospital (median OS; 26 months) was reasonable. The prognosis of MGTBC is unfavorable because the gastrointestinal tract is not a frequent site of metastasis generally and, more often than not, gastric metastasis develops at an advanced stage of breast cancer. Oligometastatic disease has better prognosis than widely metastatic disease \[[@R08]\]. The same can be said of MGTBC. The outcomes for the four patients that underwent potentially curative resection were not obvious, and curative mastectomy and mastectomy as local therapy had no significant difference in outcome. This suggests that local therapy to control the primary tumor might have equivalent benefit to curative mastectomy for oligomeric breast cancer. It is important to study some more cases with similar outcomes to establish its characteristics. The median OS in the patients treated with chemotherapy was significantly better than that in those who did not receive chemotherapy; however, this result includes factors that may lead to bias, such as age, performance status, staging of breast cancer, and comorbidity. Early detection of MGTBC is important to allow a range of treatment options, and an early diagnosis means that chemotherapy and local therapy can be performed with good outcomes.

A well-known finding for gastric metastasis in radiography is the bull's eye sign; this corresponds to the endoscopic appearance of SMT, which has a central depression. However, in our study, seven of the 11 cases had lesions with a GC-like macroscopic appearance especially that of a Borrmann type 4-like lesion. Although, there are difficulties with the macroscopic differential diagnosis in Borrmann type 4 lesions, the differential diagnosis of MGTBC and GC is significant for treatment. In general, MGTBC is treated using systemic chemotherapy (antibiotics, plant alkaloids, and monoclonal antibodies) as Stage IV breast cancer based on age, performance status, ER and HER2 status \[[@R9]-[@R11]\]. In contrast, GC is treated with surgical therapy if it is resectable without distant metastasis. It is essential to confirm a past medical history of breast cancer at the time of diagnosis. However, in four cases, the time from primary breast cancer diagnosis to the detection of gastric metastases was more than 100 months, which was sometimes too long to perform effective treatment. Histologically, ILC has a signet ring cell morphology, which can be confused with a primary gastric adenocarcinoma with poor differentiation \[[@R12]\]. Owing to an accurate histological diagnosis, deep biopsies in endoscopy are needed to obtain an appropriate specimen to distinguish MGTBC from GC because the main lesion in MGTBC is located in the submucosa \[[@R03]\]. Moreover, immunohistochemical analysis can be helpful in reaching the final diagnosis. A metastatic tumor in any organ from breast cancer is generally positive for cytokeratin (CK) 7, gross cystic disease fluid protein (GCDFP)-15, ER and progesterone receptor (PgR), and negative for CK20 \[[@R13], [@R14]\].

We experienced a case in which the endoscopic appearance of a lesion changed from SMT to Borrmann type 4 during follow-up. This suggests that MGTBC initially have a SMT-type finding. As the tumor advances, the tumor cells gradually develop in the submucosa, forming a GC-like lesion that is often accompanied by peritoneal metastasis. In this case, peritoneal dissemination was confirmed using CT when the morphologic change from SMT to Borrmann type 4 was endoscopically ascertained. Cases with Borrmann type 4 lesions also clearly have more peritoneal metastasis than those with SMT.

The present study has limitations as a result of the small number of cases. More cases need to be studied to establish the characteristics of MGTBC.

In conclusion, MGTBC is a rare entity; however, we should consider it when we find gastric tumors, especially Borrmann type 4 lesions in patients with a medical history of breast cancer. Patients with breast cancer, particularly ILC, should undergo screening EGD regularly to detect gastric metastases early and receive appropriate therapy to obtain good outcomes.
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:   metastatic gastric tumor originating from breast cancer

ILC

:   invasive lobular carcinoma
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:   infiltrating ductal carcinoma
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:   gastric cancer
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